Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
2010 · Molecular Cancer Therapeutics · 336 citations
https://doi.org/10.1158/1535-7163.mct-09-1171
N
Neil A. O’Brien
APLA Health(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
375
Papers
2.3K
Citations
27
h-index
34
i10-index
Neil A. O’Brien is an academic researcher from APLA Health. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Monoclonal and Polyclonal Antibodies Research & Advanced Breast Cancer Therapies. The author has an h-index of 27, co-authored 319 publications.
ORCID: 0000-0001-7408-1091Papers by this author
worksNeratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
2013 · Oncotarget · 162 citations
https://doi.org/10.18632/oncotarget.1148
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
2020 · Breast Cancer Research · 150 citations
https://doi.org/10.1186/s13058-020-01320-8
Current approaches and future directions in the treatment of HER2-positive breast cancer
2012 · Cancer Treatment Reviews · 147 citations
https://doi.org/10.1016/j.ctrv.2012.04.008
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
2018 · Molecular Cancer Therapeutics · 104 citations
https://doi.org/10.1158/1535-7163.mct-17-0290
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
2013 · Molecular Cancer Therapeutics · 68 citations
https://doi.org/10.1158/1535-7163.mct-12-0507
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat